View Filing Data

Exercise Price

Number of
Units

Expiry Date

October 25, 2015*

January 4, 2016

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Sep. 30, 2015	Dec. 01, 2015	Mar. 31, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Stellar Biotechnologies, Inc.
Entity Central Index Key	0001540159
Document Type	10-K
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 67,359,983
Entity Common Stock, Shares Outstanding		8,424,758
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Trading Symbol	SBOT

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Current assets:
Cash and cash equivalents	$ 3,955,503	$ 8,768,459	$ 8,423,089
Accounts receivable	157,597	44,159	56,575
Short-term investments	5,015,171	5,450,126	5,462,413
Inventory	557,280	34,891
Prepaid expenses	181,068	125,840	128,593
Total current assets	9,866,619	14,423,475	14,070,670
Noncurrent assets:
Property, plant and equipment, net	503,408	388,340	387,392
Deposits	15,900	15,900	15,900
Total noncurrent assets	519,308	404,240	403,292
Total Assets	10,385,927	14,827,715	14,473,962
Current liabilities:
Accounts payable and accrued liabilities	656,685	585,047	526,626
Deferred revenue	173,333	86,667	15,000
Warrant liability, current portion	1,550,630	460	879,040
Total current liabilities	2,380,648	672,174	1,420,666
Long-term liabilities:
Warrant liability, less current portion		3,690,806	5,352,663
Total Liabilities	2,380,648	4,362,980	6,773,329
Shareholders' equity:
Common shares, unlimited common shares authorized, no par value, 7,984,758, 7,941,985 and 7,826,885 issued and outstanding at September 30, 2015, September 30, 2014 and August 31, 2014, respectively	38,114,215	37,883,877	36,240,838
Accumulated share-based compensation	5,226,379	5,073,144	5,079,985
Accumulated deficit	(35,335,315)	(32,492,286)	(33,620,190)
Total shareholders' equity	8,005,279	10,464,735	7,700,633
Total Liabilities and Shareholders' Equity	$ 10,385,927	$ 14,827,715	$ 14,473,962

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Consolidated Balance Sheets [Abstract]
Common shares, par value
Common shares, shares issued	7,984,758	7,941,985	7,826,885
Common shares, shares outstanding	7,984,758	7,941,985	7,826,885

Consolidated Statements of Operations - USD ($)	1 Months Ended	12 Months Ended
Consolidated Statements of Operations - USD ($)	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Revenues:
Contract services revenue	$ 20,000	$ 195,000	$ 192,000	$ 60,000
Product sales	32,786	563,689	143,553	76,055
Grant revenue			36,579	409,414
Revenues	52,786	758,689	372,132	545,469
Expenses:
Costs of sales and contract services	11,636	580,824	469,149	57,351
Costs of aquaculture	22,063	259,423	254,531	137,450
Grant costs			36,579	409,414
Research and development	178,280	1,029,489	2,458,934	2,018,554
General and administration	293,130	3,227,545	2,871,455	1,770,619
Total Expenses	505,109	5,097,281	6,090,648	4,393,388
Other Income (Loss)
Foreign exchange gain (loss)	(97,866)	(653,333)	(222,437)	(95,842)
Gain (loss) in fair value of warrant liability	1,680,040	2,131,062	(2,533,305)	(10,556,208)
Investment income	1,853	54,634	61,935	4,990
Other Income (Loss), Total	1,584,027	1,532,363	(2,693,807)	(10,647,060)
Income (Loss) Before Income Tax	1,131,704	(2,806,229)	(8,412,323)	(14,494,979)
Income tax expense	3,800	36,800	27,200	800
Net Income (Loss)	$ 1,127,904	$ (2,843,029)	$ (8,439,523)	$ (14,495,779)
Income (loss) per common share - basic	$ 0.14	$ (0.36)	$ (1.11)	$ (2.81)
Income (loss) per common share - diluted	$ 0.13	$ (0.36)	$ (1.11)	$ (2.81)
Weighted average number of common shares outstanding: Basic	7,867,575	7,956,962	7,582,664	5,161,194
Weighted average number of common shares outstanding: Diluted	8,714,045	7,956,962	7,582,664	5,161,194

Consolidated Statements of Cash Flows - USD ($)	1 Months Ended	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Cash Flows Used In Operating Activities:
Net income (loss)	$ 1,127,904	$ (2,843,029)	$ (8,439,523)	$ (14,495,779)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	12,529	159,521	158,313	124,833
Share-based compensation	36,509	267,222	956,634	786,585
Foreign exchange loss	97,866	653,333	222,437	95,842
(Gain) loss in fair value of warrant liability	(1,680,040)	(2,131,062)	2,533,305	10,556,208
Loss on disposal of property, plant and equipment			3,670
Impairment loss			90,476
Fair value of shares issued for research license				491,408
Changes in working capital items:
Accounts receivable	12,352	(113,917)	121,075	(192,067)
Deferred financing costs			60,656	(62,027)
Inventory	(34,891)	(522,389)
Prepaid expenses	490	(45,758)	(94,974)	(2,658)
Accounts payable and accrued liabilities	58,922	77,018	106,224	29,309
Deferred revenue	71,667	86,666	15,000	(127,477)
Net cash used in operating activities	(296,692)	(4,412,395)	(4,266,707)	(2,795,823)
Cash Flows From Investing Activities:
Acquisition of property, plant and equipment	(13,477)	(274,589)	(279,065)	(9,541)
Proceeds on sale of property, plant and equipment			2,150
Purchase of short-term investments	(2,491)	(13,677)	(5,468,815)
Proceeds on maturities of short-term investments	2,821	410,736
Net cash provided by (used in) investing activities	(13,147)	122,470	(5,745,730)	(9,541)
Cash Flows From Financing Activities:
Proceeds from exercise of warrants and options	739,292	106,777	4,308,878	1,582,739
Proceeds from issuance of common stock, net			6,479,097	8,146,487
Refund of deposit				1,600
Net cash provided by financing activities	739,292	106,777	10,787,975	9,730,826
Effect of exchange rate changes on cash and cash equivalents	(84,083)	(629,808)	(212,338)	(64,571)
Net change in cash and cash equivalents	345,370	(4,812,956)	563,200	6,860,891
Cash and cash equivalents - beginning of year	8,423,089	8,768,459	7,859,889	998,998
Cash and cash equivalents - end of year	8,768,459	3,955,503	8,423,089	7,859,889
Cash (demand deposits)	5,895,229	3,955,503	5,474,155	6,244,049
Cash equivalents	2,873,230		2,948,934	1,615,840
Cash and cash equivalents	$ 8,768,459	$ 3,955,503	$ 8,423,089	$ 998,998

Consolidated Statements of Changes in Equity - USD ($)	Total	Common Shares [Member]	Shares Subscribed [Member]	Accumulated Share-Based Compensation [Member]	Accumulated Deficit [Member]
Balance at Aug. 31, 2012	$ 902,156	$ 8,016,895		$ 3,570,149	$ (10,684,888)
Balance (in shares) at Aug. 31, 2012		4,541,356
Proceeds of private placements	3,115,875	$ 3,115,875
Proceeds of private placements (in shares)		925,840
Issuance costs of private placements including fair value of broker units/warrants	(125,062)	$ (275,956)		150,894
Fair value of warrants issued in private placements	(1,749,004)	(1,749,004)
Proceeds from exercise of warrants	1,510,336	$ 1,510,336
Proceeds from exercise of warrants (in shares)		273,800
Transfer to common shares on exercise of warrants	2,139,409	$ 2,139,409
Proceeds from exercise of options	72,403	$ 72,403
Proceeds from exercise of options (in shares)		16,500
Transfer to common stock on exercise of options		$ 54,325		(54,325)
Share-based compensation	786,585			786,585
Shares issued to acquire license	491,408	$ 491,408
Shares issued to acquire license (in shares)		37,120
Fair value of warrants issued to acquire license		$ (195,014)		195,014
Subscriptions received for private placement and warrants	5,155,674		5,155,674
Net income/loss	(14,495,779)				(14,495,779)
Balance at Aug. 31, 2013	(2,195,999)	$ 13,180,677	5,155,674	4,648,317	(25,180,667)
Balance (in shares) at Aug. 31, 2013		5,794,616
Proceeds of private placements	7,000,000	$ 12,000,000	(5,000,000)
Proceeds of private placements (in shares)		1,142,857
Issuance costs of private placements including fair value of broker units/warrants	(520,903)	$ (907,801)		386,898
Issuance of performance shares		$ 422,728		(422,728)
Issuance of performance shares (in shares)		151,515
Proceeds from exercise of warrants	3,764,460	$ 3,920,134	(155,674)
Proceeds from exercise of warrants (in shares)		593,730
Transfer to common shares on exercise of warrants	6,591,546	$ 6,591,546
Proceeds from exercise of options	$ 544,418	$ 544,418
Proceeds from exercise of options (in shares)	144,167	144,167
Transfer to common stock on exercise of options		$ 489,136		(489,136)
Share-based compensation	956,634			956,634
Net income/loss	(8,439,523)				(8,439,523)
Balance at Aug. 31, 2014	7,700,633	$ 36,240,838		5,079,985	(33,620,190)
Balance (in shares) at Aug. 31, 2014		7,826,885
Proceeds from exercise of warrants	727,804	$ 727,804
Proceeds from exercise of warrants (in shares)		110,100
Transfer to common shares on exercise of warrants	860,397	$ 890,214		(29,817)
Proceeds from exercise of options	$ 11,488	$ 11,488
Proceeds from exercise of options (in shares)	5,000	5,000
Transfer to common stock on exercise of options		$ 13,533		(13,533)
Share-based compensation	36,509			36,509
Net income/loss	1,127,904				1,127,904
Balance at Sep. 30, 2014	10,464,735	$ 37,883,877		5,073,144	(32,492,286)
Balance (in shares) at Sep. 30, 2014		7,941,985
Proceeds from exercise of warrants	12,609	$ 12,609
Proceeds from exercise of warrants (in shares)		4,020
Transfer to common shares on exercise of warrants	9,574	$ 10,000		(426)
Proceeds from exercise of options	$ 94,168	$ 94,168
Proceeds from exercise of options (in shares)	38,750	38,753
Transfer to common stock on exercise of options		$ 113,561		(113,561)
Share-based compensation	267,222			267,222
Net income/loss	(2,843,029)				(2,843,029)
Balance at Sep. 30, 2015	$ 8,005,279	$ 38,114,215		$ 5,226,379	$ (35,335,315)
Balance (in shares) at Sep. 30, 2015		7,984,758

Nature of Operations

12 Months Ended

Sep. 30, 2015

Nature of Operations [Abstract]

Nature of Operations

Nature of Operations

Stellar Biotechnologies, Inc. (“the Company”) is organized under the laws of British Columbia, Canada. The Company's common shares are listed on the U.S. Nasdaq Capital Markets under the trading symbol “SBOT” and on the TSX Venture Exchange as a Tier 2 issuer under the trading symbol “KLH.” Prior to listing on Nasdaq effective November 5, 2015, the Company's common shares were quoted on the U.S. OTCQB Marketplace Exchange under the trading symbol SBOTF.

In April 2010, the Company changed its name to Stellar Biotechnologies, Inc. and completed a reverse merger transaction with Stellar Biotechnologies, Inc., a California corporation, which was founded in September 1999, and remains the Company's wholly-owned subsidiary and principal operating entity. The Company's executive offices are located at 332 E. Scott Street, Port Hueneme, California, 93041, USA, and the registered and records office is Royal Centre, 1055 West Georgia Street, Suite 1500, Vancouver, BC, V6E 4N7, Canada.

Nature of Operations

The Company's business is the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (“KLH”). The Company markets and distributes its KLH products to biotechnology and pharmaceutical companies, academic institutions, and clinical research organizations in Europe, the United States, and Asia.

Management Plans

For the fiscal years 2015, 2014, and 2013, the Company reported net losses of approximately $2.8 million, $8.4 million, and $14.5 million, respectively. The most significant factor in the fluctuations in net income and losses relates to noncash changes in the fair value of warrant liability, which was a gain of $2.1 million, loss of 2.5 million and loss of $10.6 million for the fiscal years 2015, 2014, and 2013, respectively. As of September 30, 2015, the Company had an accumulated deficit of approximately $35.3 million and working capital of approximately $7.5 million.

In the past, operations of the Company have primarily been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue, and product sales. In September 2013, the Company closed a private placement with gross proceeds of $12,000,000. Management believes these financial resources are adequate to support the Company's initiatives at the current level for at least 12 months. Management is also continuing the ongoing effort toward expanding the customer base for existing marketed products, and the Company may seek additional financing alternatives, including nondilutive financing through grants, collaboration and licensing arrangements, additional equity financing and debt financing.

The accompanying consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

Functional Currency

The consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company's functional currency.

Basis of Presentation

12 Months Ended

Sep. 30, 2015

Basis of Presentation [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiary, Stellar Biotechnologies, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

Change in Fiscal Year End

On June 3, 2014, the Board of Directors of the Company approved a change in the Company's fiscal year end from August 31 to September 30 of each year. This change to the calendar quarter reporting cycle began September 1, 2014. As a result of the change, the Company had a one-month transition period from September 1, 2014 to September 30, 2014. Included in this report are the Company's consolidated balance sheets as of September 30, 2015, September 30, 2014 and August 31, 2014; and the consolidated statements of operations, cash flows and changes in equity for the 12 months ended September 30, 2015 (“fiscal 2015”), August 31, 2014 (“fiscal 2014”), and August 31, 2013 (“fiscal 2013”), and the one month ended September 30, 2014.

Significant Accounting Policies

12 Months Ended

Sep. 30, 2015

Significant Accounting Policies [Abstract]

Significant Accounting Policies

3.	Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These estimates include warrant liability, share-based compensation, intangible assets, valuation of accounts receivable, valuation of inventory, and income taxes. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates, which by their nature are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Cash and Cash Equivalents

Cash and cash equivalents consist of demand deposits with financial institutions and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased.

Investments

Investments include a mutual fund of short-term fixed, floating and variable rate debt securities with normal weighted average effective maturity of approximately 1 year or less. This mutual fund investment is reported at fair value using level 1 inputs. Investments at September 30, 2014 and August 31, 2014 also include Canadian enhanced yield time deposits with an original maturity of 6 months. These enhanced yield time deposits are classified as held-to-maturity and are reported at amortized cost, which approximates fair value. The Company regularly reviews its investments in enhanced yield time deposits to determine whether a decline in fair value below the cost basis is other than temporary. If the decline in fair value is determined to be other than temporary, the cost basis of the investment is written down to fair value.

Allowance for Doubtful Accounts Receivable

The Company assesses the collectability of its accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions and credit status of its customers. As of September 30, 2015 and 2014, and August 31, 2014, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded.

Inventory

The Company records inventory at the lower of cost or market, with market not in excess of net realizable value. Raw materials are measured using FIFO (first-in first-out) cost. Work in process and finished goods are measured using average cost.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is recorded on the straight-line method over useful lives ranging from 3 to 15 years. Leasehold improvements are depreciated over the shorter of the useful life of the improvement or remaining term of lease. Maintenance and repairs are charged to operations as incurred.

Impairment of Long-Lived Assets

If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, the amount of such impairment is measured by comparing the carrying value of the asset to the fair value of the asset and the Company records the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. See Note 7 for impairment of licensing rights.

Fair Value of Financial Instruments

The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements.

Fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying value of certain financial instruments such as accounts receivable, accounts payable, accrued liabilities, and deferred revenue approximates fair value due to the short-term nature of such instruments. Canadian enhanced yield time deposits are reported at amortized cost, which approximates fair value.

The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:

Level 1:

Quoted prices in active markets for identical or similar assets and liabilities.

Level 2:

Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.

Level 3:

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company records its short-term investments in mutual fund debt securities at fair value using Level 1 inputs in the fair value hierarchy. The Company records its warrant liability at fair value using Level 2 inputs using the Black-Scholes option valuation model and assumptions disclosed in Note 9.

The following table summarizes fair values for those assets and liabilities with fair value measured on a recurring basis:

	Fair Value Measurements Using
	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
September 30, 2015
Assets
Short-term investments in mutual fund debt securities	$	5,015,171	$	-	$	-	$	5,015,171
Liabilities
Warrant liability, current portion		-		1,550,630		-		1,550,630
Warrant liability, less current portion		-		-		-		-

September 30, 2014
Assets
Short-term investments in mutual fund debt securities		5,001,494		-		-		5,001,494
Liabilities
Warrant liability, current portion		-		460		-		460
Warrant liability, less current portion		-		3,690,806		-		3,690,806

August 31, 2014
Assets
Short-term investments in mutual fund debt securities		5,004,315		-		-		5,004,315
Liabilities
Warrant liability, current portion		-		879,040		-		879,040
Warrant liability, less current portion		-		5,352,663		-		5,352,663

Revenue Recognition

Contract services revenue

The Company recognizes contract services revenue when contract services have been performed and reasonable assurance exists regarding measurement and collectability. An appropriate amount will be recognized as revenue in the period that the Company is assured of fulfilling the contract requirements. Amounts received in advance of performance of contract services are recorded as deferred revenue.

Contract services include services performed under collaboration agreements and monthly maintenance of limpet colonies through December 2014 designated to meet the needs of the customer. The Company also had the right to use raw material produced from designated limpet colonies at no cost to the Company with prior written consent from the customer.

Product Sales

The Company recognizes product sales when KLH product is shipped (for which the risk is typically transferred upon delivery to the shipping carrier) and there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectability is reasonably assured. The Company documents arrangements with customers with purchase orders and sales agreements.

Product sales include sales made under supply agreements with customers for a fixed price per gram of KLH products based on quantities ordered, including those produced from a customer's designated limpet colonies. The supply agreements are on a non-exclusive basis except within that customer's field of use.

Grants

The Company has taken the income approach to recognizing grant revenue. The Company recognizes grant revenue when there is reasonable assurance that the Company will comply with the conditions attached, the benefits have been earned and it is reasonably assured of collection. An appropriate amount of earned revenue will be recognized as revenue in the period that the Company is assured of fulfilling the grant requirements.

Research and Development

Research and development costs are expensed as incurred.

Equity Financing

The Company engages in equity financing transactions to obtain the funds necessary to continue operations and perform research and development activities. These equity financing transactions may involve issuance of common shares or units. Units typically comprise a certain number of common shares and share purchase warrants. Depending on the terms and conditions of each equity financing transaction, the warrants are exercisable into additional common shares at a price prior to expiry as stipulated by the terms of the transaction.

Share-Based Compensation

The Company grants options to buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments to non-employees.

The fair value of share-based compensation is measured on the date of grant, using the Black-Scholes option valuation model and is recognized over the vesting period net of estimated forfeitures for employees or the service period for non-employees. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option.

Foreign Exchange

Items included in the financial statements of the Company's subsidiary are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The functional currency of the parent and its subsidiary is the U.S. dollar.

Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions.

Income Taxes

Income tax expense comprises current and deferred tax. Income tax is recognized in income or loss except to the extent that it relates to items recognized directly in equity. Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively enacted at year-end, adjusted for amendments to tax payable with regards to previous years.

Deferred tax is recorded using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for relating to goodwill not deductible for tax purposes. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date.

A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. To the extent that the Company does not consider it more likely than not that a deferred tax asset will be recovered, it provides a valuation allowance against that excess.

The Company periodically evaluates its tax positions to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The Company has not incurred any interest or penalties as of September 30, 2015 with respect to uncertain income tax matters. The Company does not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12 months of the reporting date.

The Company files income tax returns in the U.S. federal and state jurisdictions and in Canada. Management believes that there are no material uncertain tax positions that would impact the accompanying consolidated financial statements. The Company's policy is to recognize interest and penalties related to unrecognized tax benefits in income tax expense. The Company may be subject to examination by the Internal Revenue Service for tax years 2011 through 2014 and by the Canada Revenue Agency for tax years 2011 through 2015. The Company may also be subject to examination on certain state and local jurisdictions for the tax years 2010 through 2014.

Earnings (Loss) Per Share

Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period.

The computation of diluted loss per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on loss per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the “if converted” method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the treasury stock method. Conversion of outstanding warrants, broker units and options would have an antidilutive effect on loss per share for the years ended September 30, 2015 and August 31, 2014 and 2013, and are therefore excluded from the computation of diluted loss per share.

Segments

The Company operates in one reportable segment and, accordingly, no segment disclosures have been presented. All equipment, leasehold improvements and other fixed assets owned by the Company are physically located within the United States (except for insignificant leasehold improvements under evaluation in Baja, Mexico), and all supply, collaboration and licensing agreements are denominated in U.S. dollars.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 creates a new topic in the Accounting Standards Codification (“ASC”) Topic 606 and establishes a new control-based revenue recognition model, changes the basis for deciding when revenue is recognized over time or at a point in time, provides new and more detailed guidance on specific topics, and expands and improves disclosures about revenue. In addition, ASU 2014-09 adds a new Subtopic to the Codification, ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers, to provide guidance on costs related to obtaining a contract with a customer and costs incurred in fulfilling a contract with a customer that are not in the scope of another ASC Topic. The guidance in ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early application is not permitted. Management is in the process of assessing the impact of ASU 2014-09 on the Company's consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The guidance in ASU 2014-15 is effective for annual reporting periods beginning after December 15, 2016, with early application permitted. Management is in the process of assessing the impact of ASU 2014-15 on the Company's consolidated financial statements.

In July 2015, FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (Topic 330). ASU 2015-11 indicates that an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The ASU does not apply to inventory measured using LIFO or the retail inventory method. It does apply to all other inventory, including inventory measured using FIFO or average cost. The guidance in ASU 2015-11 is effective for public entities for annual reporting periods beginning after December 15, 2016, including interim periods therein. The provisions should be applied prospectively with early application permitted. Management is in the process of assessing the impact of ASU 2015-11 on the Company's consolidated financial statements.

Investments

12 Months Ended

Sep. 30, 2015

Investments [Abstract]

Investments

4.	Investments

Short-term investments consisted of the following:

	September 30,		September 30,		August 31,
	2015		2014		2014

Mutual fund debt securities	$	5,015,171	$	5,001,494	$	5,004,315
Enhanced yield time deposits		-		448,632		458,098

	$	5,015,171	$	5,450,126	$	5,462,413

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Inventory

12 Months Ended

Sep. 30, 2015

Inventory [Abstract]

Inventory

5.	Inventory

Raw materials include inventory of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing and testing, and allocated manufacturing overhead for inventory in process at the end of the period. Finished goods include products that are complete and available for sale. At September 30, 2015, the Company recorded work in process and finished goods inventory only for those products with recent sales levels to evaluate net realizable value. At September 30, 2014 and prior, the Company recorded inventory only for custom manufacturing of products for specific customers, including manufacturing under supply agreements. There was no inventory for custom manufactured products at August 31, 2014. Inventory consisted of the following at September 30, 2015 and 2014:

	September 30,		September 30,
	2015		2014

Raw materials	$	42,549	$	10,480
Work in process		137,021		24,411
Finished goods		377,710		-

	$	557,280	$	34,891

Property, Plant and Equipment, net

12 Months Ended

Sep. 30, 2015

Property, Plant and Equipment, net [Abstract]

Property, Plant and Equipment, net

Property, Plant and Equipment, net

Property, plant and equipment, net consisted of the following:

	September 30,			September 30,			August 31,
	2015			2014			2014

Aquaculture system	$	124,529		$	58,923		$	58,923
Laboratory facilities		62,033			62,033			62,033
Computer and office equipment		78,936			77,697			77,697
Tools and equipment		714,764			635,766			622,289
Vehicles		10,997			10,997			10,997
Leasehold improvements		123,562			61,187			61,187

		1,114,821			906,603			893,126

Less: accumulated depreciation		(643,492	)		(518,263	)		(505,734	)

Depreciable assets, net		471,329			388,340			387,392
Construction in progress		32,079			-			-

	$	503,408		$	388,340		$	387,392

Depreciation expense amounted to $159,521, $12,529, $132,122, and $96,262 for the year ended September 30, 2015, one month ended September 30, 2014, and years ended August 31, 2014, and 2013, respectively.

Intangible Assets - Licensing Rights

12 Months Ended

Sep. 30, 2015

Intangible Assets - Licensing Rights [Abstract]

Intangible Assets - Licensing Rights

Intangible Assets - Licensing Rights

In August 2011, the Company acquired an exclusive, worldwide sub-licensable and royalty-free license for certain technology developed under collaboration with a customer. The Company paid a $200,000 license fee for the licensing rights, which are jointly owned by the Company and the customer. The licensing rights do not have a fixed term or termination provisions. The licensing rights were amortized over the estimated useful life of seven years and shown net of accumulated amortization and impairment losses. During the year ended August 31, 2014, the Company discontinued its use of these licensing rights and recorded impairment loss for the remaining value of licensing rights.

Amortization expense amounted to $26,191 and $28,571 for the years ended August 31, 2014 and 2013, respectively. Impairment loss for the year ended August 31, 2014 totaled $90,476 and is included in general and administrative expenses in the accompanying consolidated financial statements.

Commitments

12 Months Ended

Sep. 30, 2015

Commitments [Abstract]

Commitments

Commitments

Operating leases

The Company leases three buildings and facilities used in its operations under sublease agreements with the Port Hueneme Surplus Property Authority. In June 2015, the Company exercised its option to extend these sublease agreements for an additional five-year term beginning in October and November 2015. The Company negotiated an option to extend the leases for two additional five-year terms.

The Company leases facilities used for executive offices and laboratories. The Company must pay a portion of the common area maintenance. In July 2014, the Company exercised its option to extend this lease for a two-year term.

In June 2015, the Company began leasing undeveloped land in Baja California, Mexico to assess its suitability for the long-term development and potential expansion of the Company's production capability. The first two years of rent under the lease totalling $74,606 were prepaid in June 2015. The initial term is three years and the Company may terminate early with 30 days' notice. If the Company decides to proceed with development of the site, it has options to extend the lease for 30 years.

Aggregate future minimum lease payments are as follows:

	September 30,
	2015
For The Year Ending September 30,
2016	$	157,000
2017		143,000
2018		106,000
2019		106,000
2020		106,000
Thereafter		6,000

	$	624,000

Rent expense on these lease agreements amounted to approximately $192,000, $15,000, $181,000, and $178,000 for the year ended September 30, 2015, one month ended September 30, 2014, and years ended August 31, 2014, and 2013, respectively.

Purchase obligations

The Company has commitments totaling approximately $423,000 at September 30, 2015, for signed agreements with contract research organizations and consultants. The Company also has agreements to pay time and materials to contractors, which are estimated at approximately $6,000 at September 30, 2015. All purchase obligations are expected to be fulfilled within the next 12 months.

Customer supply agreements

The Company has two commitments under certain supply agreements with customers for fixed prices per gram on a non-exclusive basis except within that customer's field of use. One amended and restated supply agreement replaced two prior agreements that automatically renewed each year. The new agreement is effective March 2015 through March 2020 and is renewable for one-year terms upon written request of the customer. The other customer supply agreement is effective October 2014 through October 2019 and is renewable for one-year terms upon written request of the customer.

Licensing fees

In July 2013, the Company acquired the exclusive, worldwide license to certain patented technology for the development of human immunotherapies against Clostridium difficile infection (“C. diff”). The license agreement required an initial, non-refundable license fee of $25,000, which was paid in fiscal August 2013, and payment of an aggregate of $200,000 in delayed license fees, which were paid in fiscal August 2014. Beginning September 2014, the terms also require a license fee of $20,000 to be paid annually, creditable against royalties due, if any. Royalties are payable for a percentage of related net sales, if any. License fees are also payable for a percentage of related non-royalty sublicensing revenue, if any. No royalties have been incurred to date. The Company also reimbursed patent filing costs of approximately $52,000, $34,000 and $51,000 for the years ended September 30, 2015, and August 31, 2014, and 2013, respectively, and will reimburse certain future patent filing, prosecution, and maintenance costs. There were no patent cost reimbursements during the one month ended September 30, 2014. License fees and patent cost reimbursements have been accounted for as research and development expense in the accompanying consolidated statements of operations.

The license agreement expires when the last valid patent claim licensed under the license agreement expires, which is currently 2030. Prior to that time, the license agreement can be terminated by the licensor upon certain conditions. The Company will have 30 days after written notice from the licensor to cure the problem prior to termination of the license agreement. The Company can terminate the agreement with three months' prior written notice.

Upon execution of the license agreement, the Company issued 37,120 common shares and warrants to purchase up to 27,840 of the Company's common shares to the licensor, as further described in Note 9. The warrants expired on January 23, 2015 and were not exercised.

The license agreement provides for the Company to pay up to an aggregate of $6,020,000 in milestone payments to the licensor upon achievement of various financing and development targets up to the first regulatory approval. Remaining contingent milestone payments to the licensor totaling $57,025,000 are related to achievement of sales targets. A financing milestone was met during the year ended August 31, 2014, and accordingly, the Company made a milestone payment of $100,000. No milestones were met during the year ended August 31, 2013, or subsequent to the year ended August 31, 2014, and there can be no assurance that any of the remaining milestones will be met in the future.

Retirement savings plan 401(k) contributions

The Company sponsors a 401(k) retirement savings plan that requires an annual non-elective safe harbor employer contribution of 3% of eligible employee wages. All employees over 21 years of age are eligible beginning the first payroll after 3 consecutive months of employment. Employees are 100% vested in employer contributions and in any voluntary employee contributions. Contributions to the 401(k) plan were approximately $58,000, $5,000, $52,000, and $71,000 for the year ended September 30, 2015, one month ended September 30, 2014, and years ended August 31, 2014, and 2013, respectively.

Related party commitments

Patent royalty agreement

On August 14, 2002, through its California subsidiary, the Company entered into an agreement with a director and officer of the Company, where he would receive royalty payments in exchange for assignment of his patent rights to the Company. The royalty is 5% of gross receipts from products using this invention in excess of $500,000 annually. The Company's current operations utilize this invention. Royalty expense incurred during the year ended September 30, 2015 was approximately $1,500. There was no royalty expense incurred during the one month ended September 30, 2014 and years ended August 31, 2014 and 2013.

Collaboration agreement

In December 2013, the Company entered into a collaboration agreement with a privately-held Taiwanese biopharmaceuticals manufacturer effective through December 2015. Under the terms of the agreement, the Company will be responsible for the production and delivery of GMP grade KLH for evaluation as a carrier molecule in the collaboration partner's potential manufacture of OBI-822 active immunotherapy. The Company is also responsible for method development, product formulation, and process qualification for certain KLH reference standards. The collaboration partner will be responsible for development objectives and product specifications. The agreement provides for the collaboration partner to pay fees for certain expenses and costs associated with the collaboration. Subject to certain conditions and timing, the collaboration also provides for the parties to negotiate a commercial supply agreement for Stellar KLH™ in the future. However, there can be no assurance that any such negotiations will lead to successful execution of any further agreements related to this collaboration.

The privately-held Taiwanese biopharmaceuticals manufacturer is a beneficial owner of over 5% of the Company's common shares. In addition, a member of the Company's Board of Directors currently serves as General Manager and chair of its board of directors.

Share Capital

12 Months Ended

Sep. 30, 2015

Share Capital [Abstract]

Share Capital

Share Capital

On September 2, 2015, the Company effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-10. As a result of the reverse split, every ten shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share. The reverse split reduced the number of common shares outstanding from 79,847,550 to 7,984,758 after fractional share rounding. The number of warrants, broker units, and options were proportionately adjusted by the split ratio and the exercise prices correspondingly increased by the same split ratio. All shares and exercise prices are presented on a post-split basis in these consolidated financial statements.

The Company had the following transactions in share capital:

			One Month
	Year Ended		Ended		Year Ended
	September 30,		September 30,		August 31,		August 31,
	2015		2014		2014		2013

Number of common shares issued		42,773		115,100		2,032,269		1,253,260

Proceeds from exercise of warrants and broker units	$	12,609	$	727,804	$	3,764,460	$	1,510,336
Transfer to common shares on exercise of warrants and broker units		10,000		890,214		6,591,546		2,139,409
Proceeds from exercise of options		94,168		11,488		544,418		72,403
Transfer to common shares on exercise of options		113,561		13,533		489,136		54,325
Share-based compensation		267,222		36,509		956,634		786,585

Performance Shares

There were 1,000,000 common shares allotted as performance shares to be issued to certain officers, directors and employees of the Company based on meeting milestones related to completion of method development for commercial-scale manufacture of KLH, compilation and regulatory submittal of all required chemistry, manufacturing and control data and completion of preclinical toxicity and immunogenicity testing of products under a performance share plan. Share-based compensation was recorded over the estimated vesting period ending in August 2012.

At September 30, 2015, there are 383,838 performance shares reserved for issuance.

License Agreement

During the year ended August 31, 2013, the Company entered into a license agreement and issued 37,120 common shares and warrants to purchase up to 27,840 of the Company's common shares to the licensor. Each warrant entitled the holder to purchase one common share of the Company at a price of CDN$12.50 per share on or before January 23, 2015. The common shares were subject to a hold period that ended on November 25, 2013. The warrants expired on January 23, 2015 and were not exercised. The value of the shares and warrants were recorded as research and development expense.

Black-Scholes option valuation model

The Company uses the Black-Scholes option valuation model to determine the fair value of warrants, broker units and share options. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company has used historical volatility to estimate the volatility of the share price. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company's warrants, broker units and share options.

Warrants

A summary of the Company's warrants activity is as follows:

	Number of Warrants			Weighted Average Exercise Price

Balance - August 31, 2013		1,132,630		$	5.70	CDN $

Granted		3,810			4.60	CDN $
Granted		604,761			13.30
Exercised		(583,230	)		6.80	CDN $
Exercised		(6,000	)		13.50

Balance - August 31, 2014		1,151,971			9.70	CDN $

Granted		4,260			7.50	CDN $
Exercised		(101,700	)		7.50	CDN $

Balance - September 30, 2014		1,054,531			10.10	CDN $

Exercised		(3,900	)		4.05	CDN $
Expired		(27,870	)		12.50	CDN $

Balance - September 30, 2015		1,022,761		$	12.12	CDN $

The weighted average contractual life remaining on the outstanding warrants at September 30, 2015 is 7 months.

The following table summarizes information about the warrants outstanding at September 30, 2015:

Exercise Price	Number of Warrants		Expiry Date

CDN$4.00		400,000	October 25, 2015*
CDN$4.00		24,000	January 4, 2016
$13.50		470,190	September 9, 2016
$10.50		20,000	September 9, 2016	Broker warrants
$13.50		95,238	September 20, 2016
$10.50		13,333	September 20, 2016	Broker warrants

		1,022,761

* Subsequently exercised.

Warrant Liability

Equity offerings conducted by the Company in prior years included the issuance of warrants with exercise prices denominated in Canadian dollars. The Company's functional currency is in U.S. dollars. As a result of having exercise prices denominated in other than the Company's functional currency, these warrants meet the definition of derivatives and are therefore classified as derivative liabilities measured at fair value with adjustments to fair value recognized through the consolidated statements of operations. As these warrants are exercised, the fair value of the recorded warrant liability on date of exercise is included in common shares along with the proceeds from the exercise. If these warrants expire, the related decrease in warrant liability is recognized in profit or loss, as part of the change in fair value of warrant liability. There is no cash flow impact as a result of this accounting treatment.

The fair value of the warrants is determined using the Black-Scholes option valuation model at the end of each reporting period. Upon exercise of the warrants, the fair value of warrants included in derivative liabilities is reclassified to equity.

The fair value of warrants exercised was determined using the Black-Scholes option valuation model, using the following weighted average assumptions:

			One Month
	Year Ended		Ended		Year Ended
	September 30,		September 30,		August 31,		August 31,
	2015		2014		2014		2013
Risk free interest rate		0.44%		1.12%		1.07%		1.23%
Expected life (years)		0.4		0.03		0.27		1.17
Expected share price volatility		92%		97%		106%		111%

There were no warrants granted during the year ended September 30, 2015 or the one month ended September 30, 2014. The fair value of warrants granted was determined using the Black-Scholes option valuation model, using the following weighted average assumptions at the date of the grant:

	Year Ended
	August 31,		August 31,
	2014		2013
Risk free interest rate		1.48%		1.18%
Expected life (years)		3.00		2.76
Expected share price volatility		112%		123%
Expected dividend yield		0%		0%

Broker units

The Company granted broker units as finders' fees in conjunction with equity offerings in prior years. Broker units are fully vested when granted and allow the holders to purchase equity units. A unit consists of one common share and either one whole warrant or one half warrant.

A summary of broker units activity is as follows:

	Number of Units			Weighted Average Exercise Price

Balance - August 31, 2013		59,620		$	2.90	CDN $

Exercised		(4,500	)		3.30	CDN $

Balance - August 31, 2014		55,120			2.90	CDN $

Exercised		(8,400	)		5.00	CDN $

Balance - September 30, 2014		46,720			2.51	CDN $

Exercised		(120	)		5.00	CDN $

Balance - September 30, 2015		46,600		$	2.50	CDN $

The weighted average contractual life remaining on the outstanding broker units is 1 month.

The following table summarizes information about the broker units outstanding at September 30, 2015:

* Subsequently exercised.

The outstanding broker units include one warrant.

There were no broker units granted during the year ended September 30, 2015, the one month ended September 30, 2014, or the year ended August 31, 2014. The estimated fair value of the broker units granted was determined using a Black-Scholes option valuation model with the following weighted average assumptions:

	Year Ended
	August 31,
	2013
Risk free interest rate		1.17	%
Expected life (years)		2.83
Expected share price volatility		123	%
Expected dividend yield		0	%

The weighted average fair value of broker units granted during the year ended August 31, 2013 was CDN$2.50.

Options

The Company has a fixed share option plan adopted in 2013 (“the Plan”) to be administered by the Board of Directors, which has the discretion to grant up to an aggregate of 1,000,000 options. The exercise price of an option is set at the closing price of the Company's common shares on the date of grant. Share options granted to directors, officers, employees and consultants are subject to the following vesting schedule:

(a)

One-third shall vest immediately;

(b)

One-third shall vest 12 months from the date of grant; and

(c)

One-third shall vest 18 months from the date of grant.

Share options granted to investor relations consultants vest over a period of not less than 12 months as to 25% on the date that is three months from the date of grant, and a further 25% on each successive date that is three months from the date of the prior vesting.

Options have been issued under the Plan allowing the holders to purchase common shares of the Company as follows:

	Number of Options			Weighted Average Exercise Price

Balance - August 31, 2013		658,887		$	4.20	CDN $

Granted		19,500			14.20	CDN $
Granted		59,500			18.30
Exercised		(144,167	)		4.10	CDN $
Expired		(167	)		4.20	CDN $

Balance - August 31, 2014		593,553			6.10	CDN $

Exercised		(5,000	)		2.50	CDN $

Balance - September 30, 2014		588,553			6.20	CDN $

Granted		16,500			13.30	CDN $
Exercised		(38,750	)		3.06	CDN $
Expired		(8,665	)		14.21	CDN $

Balance - September 30, 2015		557,638		$	6.93	CDN $

The weighted average contractual life remaining on the outstanding options is 3.19 years.

The following table summarizes information about the options under the Plan outstanding and exercisable at September 30, 2015:

Number of Options		Exercisable at September 30, 2015		Range of exercise prices		Expiry Dates
	306,110		306,110		CDN$0.00 - 5.00	Apr 2017-Dec 2019
	173,861		169,027		CDN$5.01 - 10.00	Oct 2017-Jun 2022
	21,500		13,833		CDN$15.01 - 20.00	Nov 2018-Nov 2021
	56,167		56,167		$15.01 - 20.00	Nov 2020
	557,638		545,137

There were no share options granted in the one month ended September 30, 2014. The estimated fair value of the share options granted was determined using a Black-Scholes option valuation model with the following weighted average assumptions:

	Year Ended
	September 30,			August 31,			August 31,
	2015			2014			2013
Risk free interest rate		1.65	%		2.01	%		1.55	%
Expected life (years)		7.00			6.75			6.17
Expected share price volatility		115	%		120	%		123	%
Expected dividend yield		0	%		0	%		0	%

The weighted average fair value of share options awarded during the years ended September 30, 2015, and August 31, 2014 and 2013 was CDN$11.72, CDN$15.80, and CDN$3.80, respectively.

As of September 30, 2015, the Company had approximately $38,000 of unrecognized share-based compensation expense, which is expected to be recognized over a period of 1.25 years.

The intrinsic value of the options exercised during the year ended September 30, 2015, one month ended September 30, 2014, and years ended August 31, 2014, and 2013 was CDN$10.14, CDN$17.40, CDN$13.76, and CDN$6.67 respectively. The intrinsic value of the vested options at September 30, 2015 was $3.95

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Income Taxes

12 Months Ended

Sep. 30, 2015

Income Taxes [Abstract]

Income Taxes

10.

Income Taxes

The breakdown of loss before income tax by jurisdiction is as follows:

	September 30, 2015			September 30, 2014			August 31, 2014			August 31, 2013

U.S.	$	(3,258,355	)	$	(334,841	)	$	(4,183,392	)	$	(2,082,441	)
Canadian		405,203			1,462,652			(4,096,931	)		(12,412,538	)
Other foreign		46,923			3,893			(132,000	)		-

Total Loss Before Income Tax	$	(2,806,229	)	$	1,131,704		$	(8,412,323	)	$	(14,494,979	)

Deferred income tax assets and liabilities of the Company at September 30, 2015 and 2014 and August 31, 2014 and 2013 are as follows:

	September 30, 2015			September 30, 2014			August 31, 2014			August 31, 2013

Deferred income tax assets:
Non-capital loss carry-forwards	$	8,028,900		$	6,561,000		$	6,418,300		$	4,426,800
Research and development tax credits		716,400			626,900			616,600			450,400
Deferred expenses		82,900			84,000			90,000			65,100
Property, plant and equipment		1,700			-			-			-
Share issuance costs		67,800			124,700			131,800			63,300
Deferred income tax liabilities:
U.S. federal benefit net of state taxes		(628,800	)		(517,100	)		(509,000	)		(350,600	)
Property, plant and equipment		-			(13,600	)		(14,500	)		(33,400	)
Valuation allowance		(8,268,900	)		(6,865,900	)		(6,733,200	)		(4,621,600	)

Net deferred income tax asset (liability)	$	-		$	-		$	-		$	-

Realization of the deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance.

As of September 30, 2015, the Company had federal net operating loss (“NOL”) carryforwards of approximately $16,685,000 expiring 2030 through 2035, California NOL carryforwards of approximately $16,455,000 expiring 2016 through 2035, and Canadian federal and provincial NOL carryforwards of approximately CDN$4,647,000 expiring 2028 through 2035. Portions of these NOL carryforwards may be used to offset future taxable income, if any.

As of September 30, 2015, the Company also has federal and California research and development tax credit carryforwards of approximately $339,000 and $377,000, respectively, available to offset future taxes. The federal credits begin expiring in 2024 and continue expiring through 2035. The state tax credits do not expire.

Under the provisions of Section 382 of the Internal Revenue Code, substantial changes in the Company's ownership limit the amount of net operating loss carryforwards and tax credit carryforwards that can be utilized annually in the future to offset taxable income. A valuation allowance has been established to reserve the potential benefits of these carryforwards in the Company's consolidated financial statements to reflect the uncertainty of future taxable income required to utilize available tax loss carryforwards and other deferred tax assets.

The recovery of income taxes shown in the consolidated statements of operations differs from the amounts obtained by applying statutory rates to the loss before provision for income taxes due to the following:

	September 30, 2015			September 30, 2014			August 31, 2014			August 31, 2013

Combined Canadian federal and provincial tax rates		26.0	%		26.0	%		26.0	%		25.0	%

Expected income tax (recovery)/expense	$	(729,600	)	$	294,300		$	(2,187,200	)	$	(3,623,700	)

Nondeductible share-based payments		69,500			9,500			248,700			327,000
Nondeductible change in fair value of warrant liability		(554,100	)		(436,800	)		659,300			2,807,300
Effect of higher income tax rate in U.S.		(445,800	)		(46,000	)		(602,100	)		(308,400	)
Foreign currency differences		169,900			25,400			(50,900	)		(26,300	)
Other		(43,300	)		(3,800	)		(219,800	)		(322,500	)
Change in valuation allowance on deferred tax assets		1,570,200			161,200			2,179,200			1,147,400

Income tax expense	$	36,800		$	3,800		$	27,200		$	800

The components of income tax provision (benefits) are as follows:

	September 30, 2015			September 30, 2014			August 31, 2014			August 31, 2013

Current tax provision
U.S. federal	$	-		$	-		$	-		$	-
Canadian		-			-			-			-
Other foreign		36,000			3,000			26,400			-
State		800			800			800			800

Deferred tax provision
U.S. federal		(1,032,200	)		(107,100	)		(1,431,400	)		(738,000	)
Canadian		(209,300	)		(21,600	)		(289,800	)		(157,500	)
State		(328,700	)		(32,500	)		(458,000	)		(251,900	)

Change in valuation allowance on deferred tax assets		1,570,200			161,200			2,179,200			1,147,400

Total	$	36,800		$	3,800		$	27,200		$	800

Supplemental Disclosure of Cash Flow and Non-Cash Transactions

12 Months Ended

Sep. 30, 2015

Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]

Supplemental Disclosure of Cash Flow and Non-Cash Transactions

11.

Supplemental Disclosure of Cash Flow and Non-Cash Transactions

Supplemental disclosure of cash flow information follows:

			One Month
	Year Ended		Ended		Year Ended
	September 30,		September 30,		August 31,		August 31,
	2015		2014		2014		2013
Cash paid during the period for taxes	$	36,800	$	800	$	30,200	$	800

Supplemental disclosure of non-cash financing and investing activities follows:

			One Month
	Year Ended		Ended		Year Ended
	September 30,		September 30,		August 31,		August 31,
	2015		2014		2014		2013

Share issuance costs - broker units and warrants	$	-	$	-	$	386,898	$	150,894
Transfer to common shares on exercise of warrants and broker units		10,000		890,214		6,591,546		2,139,409
Transfer to common shares on exercise of options		113,561		13,533		489,136		54,325
Transfer to common shares on issuance of performance shares		-		-		422,728		-
Shares subscribed transferred to common shares		-		-		5,155,674		-
Warrant valuations on private placements		-		-		-		1,749,004
Fair value of shares issued for acquisition of license		-		-		-		491,408
Warrant valuation on acquisition of license		-		-		-		195,014

Concentrations of Credit Risk

12 Months Ended

Sep. 30, 2015

Concentrations of Credit Risk [Abstract]

Concentrations of Credit Risk

12.

Concentrations of Credit Risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, mutual fund debt securities and accounts receivable. The Company estimates its maximum credit risk at the amount recorded on the balance sheet.

Management's assessment of the Company's credit risk for cash and cash equivalents is low as they are held in major financial institutions believed to be credit worthy. The Company limits its exposure to credit loss for short-term investments by using a mutual fund that invests in high-quality, U.S. dollar-denominated short-term fixed-, floating- and variable-rate debt securities that have received either a minimum short-term rating of at least A-1 (or its equivalent) or a minimum long-term rating of A minus (or its equivalent), by one or more Nationally Recognized Statistical Ratings Organizations, or, if unrated, that are deemed by the fund to be of comparable quality at the time of purchase. Based on credit monitoring and history, the Company considers the risk of credit losses due to customer non-performance on accounts receivable to be low.

The Company had the following concentrations of revenues by customers and grantors:

		One Month
	Year Ended	Ended	Year Ended
	September 30,	September 30,	August 31,	August 31,
	2015	2014	2014	2013

Product sales and contract services revenue	85% from 5 customers	86% from 3 customers	73% from 2 customers	73% from 2 customers

Grant revenue	-	-	100% from 1 grantor	100% from 1 grantor

The Company had the following concentrations of revenues by geographic areas:

				One Month
	Year Ended			Ended			Year Ended
	September 30,			September 30,			August 31,			August 31,
	2015			2014			2014			2013

Europe		53	%		9	%		41	%		84	%
Asia		38	%		28	%		40	%		-
U.S.		9	%		62	%		14	%		12	%
Other countries		-			-			6	%		4	%

The Company had the following concentrations of accounts receivable:

		One Month
	Year Ended	Ended	Year Ended
	September 30,	September 30,	August 31,	August 31,
	2015	2014	2014	2013

Accounts receivable	91% from 2 customers	81% from 2 customers	76% from 1 customer	88% from 1 grantor

Reclassifications	12 Months Ended
Reclassifications	Sep. 30, 2015
Reclassifications [Abstract]
Reclassifications	13. Reclassifications Certain reclassifications have been made to prior years to conform with the current year's presentation. These include the Company's reclassification of a mutual fund investing in short-term debt securities from cash equivalents to short-term investments and reclassification of costs related to aquaculture to present such costs separately from costs of sales and contract services. There was no impact on total assets, total shareholders' equity, accumulated deficit, total expenses or net income (loss) resulting from these reclassifications.

- Definition

The entire disclosure for any adjustments made during the period to avoid double counting in comprehensive income items displayed as part of net income that also had been displayed as part of other comprehensive income in that period or earlier periods. These adjustments include reclassifications to net income of items in accumulated comprehensive income, such as deferred gains or losses on qualifying hedges when hedged item reported in net income, holding gains or losses on available-for-sale securities transferred into trading category, unrealized holding gains or losses on debt securities transferred from held-to-maturity category into available-for-sale category and accumulated translation adjustment attributable to foreign subsidiary or investment in foreign entity upon sale or liquidation.

+ References + Details

Subsequent Event	12 Months Ended
Subsequent Event	Sep. 30, 2015
Subsequent Event [Abstract]
Subsequent Event	14. Subsequent Events Subsequent to September 30, 2015, the Company issued 440,000 common shares upon the exercise of 400,000 warrants and 40,000 broker units for gross proceeds of CDN$1,700,000 through December 1, 2015.

Significant Accounting Policies (Policies)

12 Months Ended

Sep. 30, 2015

Significant Accounting Policies [Abstract]

Use of Estimates

Cash and Cash Equivalents

Investment

Investments

Allowance for Doubtful Accounts Receivable

Inventory

Property, Plant and Equipment

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

Level 1:

Quoted prices in active markets for identical or similar assets and liabilities.

Level 2:

Level 3:

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table summarizes fair values for those assets and liabilities with fair value measured on a recurring basis:

	Fair Value Measurements Using
	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
September 30, 2015
Assets
Short-term investments in mutual fund debt securities	$	5,015,171	$	-	$	-	$	5,015,171
Liabilities
Warrant liability, current portion		-		1,550,630		-		1,550,630
Warrant liability, less current portion		-		-		-		-

September 30, 2014
Assets
Short-term investments in mutual fund debt securities		5,001,494		-		-		5,001,494
Liabilities
Warrant liability, current portion		-		460		-		460
Warrant liability, less current portion		-		3,690,806		-		3,690,806

August 31, 2014
Assets
Short-term investments in mutual fund debt securities		5,004,315		-		-		5,004,315
Liabilities
Warrant liability, current portion		-		879,040		-		879,040
Warrant liability, less current portion		-		5,352,663		-		5,352,663

Revenue Recognition

Contract services revenue

Product Sales

Grants

Research and Development

Research and development costs are expensed as incurred.

Equity Financing

Share-based Compensation

Share-Based Compensation

The Company grants options to buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments to non-employees.

Foreign Exchange

Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions.

Income Taxes

Earnings (Loss) Per Share

Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period.

Segments

Recent Accounting Pronouncements

Significant Accounting Policies (Tables)

12 Months Ended

Sep. 30, 2015

Significant Accounting Policies [Abstract]

Schedule of Assets and Liabilities with Fair Value Measured on a Recurring Basis

	Fair Value Measurements Using
	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
September 30, 2015
Assets
Short-term investments in mutual fund debt securities	$	5,015,171	$	-	$	-	$	5,015,171
Liabilities
Warrant liability, current portion		-		1,550,630		-		1,550,630
Warrant liability, less current portion		-		-		-		-

September 30, 2014
Assets
Short-term investments in mutual fund debt securities		5,001,494		-		-		5,001,494
Liabilities
Warrant liability, current portion		-		460		-		460
Warrant liability, less current portion		-		3,690,806		-		3,690,806

August 31, 2014
Assets
Short-term investments in mutual fund debt securities		5,004,315		-		-		5,004,315
Liabilities
Warrant liability, current portion		-		879,040		-		879,040
Warrant liability, less current portion		-		5,352,663		-		5,352,663

Investments (Tables)

12 Months Ended

Sep. 30, 2015

Investments [Abstract]

Investments

	September 30,		September 30,		August 31,
	2015		2014		2014

Mutual fund debt securities	$	5,015,171	$	5,001,494	$	5,004,315
Enhanced yield time deposits		-		448,632		458,098

	$	5,015,171	$	5,450,126	$	5,462,413

Inventory (Tables)

12 Months Ended

Sep. 30, 2015

Inventory [Abstract]

Inventory

	September 30,		September 30,
	2015		2014

Raw materials	$	42,549	$	10,480
Work in process		137,021		24,411
Finished goods		377,710		-

	$	557,280	$	34,891

Property, Plant and Equipment, net (Tables)

12 Months Ended

Sep. 30, 2015

Property, Plant and Equipment, net [Abstract]

Property, Plant and Equipment, net

	September 30,			September 30,			August 31,
	2015			2014			2014

Aquaculture system	$	124,529		$	58,923		$	58,923
Laboratory facilities		62,033			62,033			62,033
Computer and office equipment		78,936			77,697			77,697
Tools and equipment		714,764			635,766			622,289
Vehicles		10,997			10,997			10,997
Leasehold improvements		123,562			61,187			61,187

		1,114,821			906,603			893,126

Less: accumulated depreciation		(643,492	)		(518,263	)		(505,734	)

Depreciable assets, net		471,329			388,340			387,392
Construction in progress		32,079			-			-

	$	503,408		$	388,340		$	387,392

Commitments (Tables)

12 Months Ended

Sep. 30, 2015

Commitments [Abstract]

Schedule of Future Minimum Lease Payments

	September 30,
	2015
For The Year Ending September 30,
2016	$	157,000
2017		143,000
2018		106,000
2019		106,000
2020		106,000
Thereafter		6,000

	$	624,000

Share Capital (Tables)

12 Months Ended

Sep. 30, 2015

Share Capital [Abstract]

Transactions In Share Capital

			One Month
	Year Ended		Ended		Year Ended
	September 30,		September 30,		August 31,		August 31,
	2015		2014		2014		2013

Number of common shares issued		42,773		115,100		2,032,269		1,253,260

Proceeds from exercise of warrants and broker units	$	12,609	$	727,804	$	3,764,460	$	1,510,336
Transfer to common shares on exercise of warrants and broker units		10,000		890,214		6,591,546		2,139,409
Proceeds from exercise of options		94,168		11,488		544,418		72,403
Transfer to common shares on exercise of options		113,561		13,533		489,136		54,325
Share-based compensation		267,222		36,509		956,634		786,585

Schedule of Warrant Activity

	Number of Warrants			Weighted Average Exercise Price

Balance - August 31, 2013		1,132,630		$	5.70	CDN $

Granted		3,810			4.60	CDN $
Granted		604,761			13.30
Exercised		(583,230	)		6.80	CDN $
Exercised		(6,000	)		13.50

Balance - August 31, 2014		1,151,971			9.70	CDN $

Granted		4,260			7.50	CDN $
Exercised		(101,700	)		7.50	CDN $

Balance - September 30, 2014		1,054,531			10.10	CDN $

Exercised		(3,900	)		4.05	CDN $
Expired		(27,870	)		12.50	CDN $

Balance - September 30, 2015		1,022,761		$	12.12	CDN $

Summary of Warrants Outstanding

Exercise Price	Number of Warrants		Expiry Date

CDN$4.00		400,000	October 25, 2015*
CDN$4.00		24,000	January 4, 2016
$13.50		470,190	September 9, 2016
$10.50		20,000	September 9, 2016	Broker warrants
$13.50		95,238	September 20, 2016
$10.50		13,333	September 20, 2016	Broker warrants

		1,022,761

* Subsequently exercised.

Schedule of Broker Units Activity

	Number of Units			Weighted Average Exercise Price

Balance - August 31, 2013		59,620		$	2.90	CDN $

Exercised		(4,500	)		3.30	CDN $

Balance - August 31, 2014		55,120			2.90	CDN $

Exercised		(8,400	)		5.00	CDN $

Balance - September 30, 2014		46,720			2.51	CDN $

Exercised		(120	)		5.00	CDN $

Balance - September 30, 2015		46,600		$	2.50	CDN $

Summary Of Broker Units Outstanding

* Subsequently exercised.

Schedule of Share Options Activity

	Number of Options			Weighted Average Exercise Price

Balance - August 31, 2013		658,887		$	4.20	CDN $

Granted		19,500			14.20	CDN $
Granted		59,500			18.30
Exercised		(144,167	)		4.10	CDN $
Expired		(167	)		4.20	CDN $

Balance - August 31, 2014		593,553			6.10	CDN $

Exercised		(5,000	)		2.50	CDN $

Balance - September 30, 2014		588,553			6.20	CDN $

Granted		16,500			13.30	CDN $
Exercised		(38,750	)		3.06	CDN $
Expired		(8,665	)		14.21	CDN $

Balance - September 30, 2015		557,638		$	6.93	CDN $

Summary of Options Outstanding And Exercisable

Number of Options		Exercisable at September 30, 2015		Range of exercise prices		Expiry Dates
	306,110		306,110		CDN$0.00 - 5.00	Apr 2017-Dec 2019
	173,861		169,027		CDN$5.01 - 10.00	Oct 2017-Jun 2022
	21,500		13,833		CDN$15.01 - 20.00	Nov 2018-Nov 2021
	56,167		56,167		$15.01 - 20.00	Nov 2020
	557,638		545,137

Schedule of Share-based Payment Award, Share Options, Valuation Assumptions

	Year Ended
	September 30,			August 31,			August 31,
	2015			2014			2013
Risk free interest rate		1.65	%		2.01	%		1.55	%
Expected life (years)		7.00			6.75			6.17
Expected share price volatility		115	%		120	%		123	%
Expected dividend yield		0	%		0	%		0	%

Warrants Exercised [Member]

Class of Warrant or Right [Line Items]

Schedule of Fair Value Measurement Assumptions

			One Month
	Year Ended		Ended		Year Ended
	September 30,		September 30,		August 31,		August 31,
	2015		2014		2014		2013
Risk free interest rate		0.44%		1.12%		1.07%		1.23%
Expected life (years)		0.4		0.03		0.27		1.17
Expected share price volatility		92%		97%		106%		111%

Warrants Granted [Member]

Class of Warrant or Right [Line Items]

Schedule of Fair Value Measurement Assumptions

	Year Ended
	August 31,		August 31,
	2014		2013
Risk free interest rate		1.48%		1.18%
Expected life (years)		3.00		2.76
Expected share price volatility		112%		123%
Expected dividend yield		0%		0%

Broker Units Granted [Member]

Class of Warrant or Right [Line Items]

Schedule of Fair Value Measurement Assumptions

	Year Ended
	August 31,
	2013
Risk free interest rate		1.17	%
Expected life (years)		2.83
Expected share price volatility		123	%
Expected dividend yield		0	%

Income Taxes (Tables)

12 Months Ended

Sep. 30, 2015

Income Taxes [Abstract]

Schedule of Breakdown of Loss Before Income Tax by Jurisdiction

	September 30, 2015			September 30, 2014			August 31, 2014			August 31, 2013

U.S.	$	(3,258,355	)	$	(334,841	)	$	(4,183,392	)	$	(2,082,441	)
Canadian		405,203			1,462,652			(4,096,931	)		(12,412,538	)
Other foreign		46,923			3,893			(132,000	)		-

Total Loss Before Income Tax	$	(2,806,229	)	$	1,131,704		$	(8,412,323	)	$	(14,494,979	)

Schedule of Deferred Tax Assets and Liabilities

	September 30, 2015			September 30, 2014			August 31, 2014			August 31, 2013

Deferred income tax assets:
Non-capital loss carry-forwards	$	8,028,900		$	6,561,000		$	6,418,300		$	4,426,800
Research and development tax credits		716,400			626,900			616,600			450,400
Deferred expenses		82,900			84,000			90,000			65,100
Property, plant and equipment		1,700			-			-			-
Share issuance costs		67,800			124,700			131,800			63,300
Deferred income tax liabilities:
U.S. federal benefit net of state taxes		(628,800	)		(517,100	)		(509,000	)		(350,600	)
Property, plant and equipment		-			(13,600	)		(14,500	)		(33,400	)
Valuation allowance		(8,268,900	)		(6,865,900	)		(6,733,200	)		(4,621,600	)

Net deferred income tax asset (liability)	$	-		$	-		$	-		$	-

Schedule of Effective Income Tax Rate Reconciliation

	September 30, 2015			September 30, 2014			August 31, 2014			August 31, 2013

Combined Canadian federal and provincial tax rates		26.0	%		26.0	%		26.0	%		25.0	%

Expected income tax (recovery)/expense	$	(729,600	)	$	294,300		$	(2,187,200	)	$	(3,623,700	)

Nondeductible share-based payments		69,500			9,500			248,700			327,000
Nondeductible change in fair value of warrant liability		(554,100	)		(436,800	)		659,300			2,807,300
Effect of higher income tax rate in U.S.		(445,800	)		(46,000	)		(602,100	)		(308,400	)
Foreign currency differences		169,900			25,400			(50,900	)		(26,300	)
Other		(43,300	)		(3,800	)		(219,800	)		(322,500	)
Change in valuation allowance on deferred tax assets		1,570,200			161,200			2,179,200			1,147,400

Income tax expense	$	36,800		$	3,800		$	27,200		$	800

Schedule of Components of Income Tax Expense (Benefit)

	September 30, 2015			September 30, 2014			August 31, 2014			August 31, 2013

Current tax provision
U.S. federal	$	-		$	-		$	-		$	-
Canadian		-			-			-			-
Other foreign		36,000			3,000			26,400			-
State		800			800			800			800

Deferred tax provision
U.S. federal		(1,032,200	)		(107,100	)		(1,431,400	)		(738,000	)
Canadian		(209,300	)		(21,600	)		(289,800	)		(157,500	)
State		(328,700	)		(32,500	)		(458,000	)		(251,900	)

Change in valuation allowance on deferred tax assets		1,570,200			161,200			2,179,200			1,147,400

Total	$	36,800		$	3,800		$	27,200		$	800

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Tables)

12 Months Ended

Sep. 30, 2015

Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]

Supplemental Disclosure of Cash Flow Information

			One Month
	Year Ended		Ended		Year Ended
	September 30,		September 30,		August 31,		August 31,
	2015		2014		2014		2013
Cash paid during the period for taxes	$	36,800	$	800	$	30,200	$	800

Supplemental Disclosure of Non-Cash Financing and Investing Activities

			One Month
	Year Ended		Ended		Year Ended
	September 30,		September 30,		August 31,		August 31,
	2015		2014		2014		2013

Share issuance costs - broker units and warrants	$	-	$	-	$	386,898	$	150,894
Transfer to common shares on exercise of warrants and broker units		10,000		890,214		6,591,546		2,139,409
Transfer to common shares on exercise of options		113,561		13,533		489,136		54,325
Transfer to common shares on issuance of performance shares		-		-		422,728		-
Shares subscribed transferred to common shares		-		-		5,155,674		-
Warrant valuations on private placements		-		-		-		1,749,004
Fair value of shares issued for acquisition of license		-		-		-		491,408
Warrant valuation on acquisition of license		-		-		-		195,014

Concentrations of Credit Risk (Tables)

12 Months Ended

Sep. 30, 2015

Concentrations of Credit Risk [Abstract]

Schedules of Concentration of Credit Risk

		One Month
	Year Ended	Ended	Year Ended
	September 30,	September 30,	August 31,	August 31,
	2015	2014	2014	2013

Product sales and contract services revenue	85% from 5 customers	86% from 3 customers	73% from 2 customers	73% from 2 customers

Grant revenue	-	-	100% from 1 grantor	100% from 1 grantor

				One Month
	Year Ended			Ended			Year Ended
	September 30,			September 30,			August 31,			August 31,
	2015			2014			2014			2013

Europe		53	%		9	%		41	%		84	%
Asia		38	%		28	%		40	%		-
U.S.		9	%		62	%		14	%		12	%
Other countries		-			-			6	%		4	%

		One Month
	Year Ended	Ended	Year Ended
	September 30,	September 30,	August 31,	August 31,
	2015	2014	2014	2013

Accounts receivable	91% from 2 customers	81% from 2 customers	76% from 1 customer	88% from 1 grantor

Nature of Operations (Details) - USD ($)	1 Months Ended		12 Months Ended
Nature of Operations (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Nature of Operations [Abstract]
Net Income (Loss) Attributable to Parent	$ 1,127,904		$ (2,843,029)	$ (8,439,523)	$ (14,495,779)
Accumulated deficit	$ (32,492,286)		(35,335,315)	$ (33,620,190)
Working capital			$ 7,500,000
Proceeds from a private placement		$ 12,000,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Significant Accounting Policies (Details) - USD ($)	12 Months Ended
Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Significant Accounting Policies Disclosure [Line Items]
Allowance for doubtful accounts
Minimum [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, plant and equipment, useful lives	3 years
Maximum [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, plant and equipment, useful lives	15 years

Significant Accounting Policies (Schedule of Assets and Liabilities with Fair Value Measured on a Recurring Basis) (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Liabilities
Warrant liability, current portion	$ 1,550,630	$ 460	$ 879,040
Warrant liability, less current portion		3,690,806	5,352,663
Recurring [Member]
Assets
Short-term investments in mutual fund debt securities	5,015,171	5,001,494	5,004,315
Liabilities
Warrant liability, current portion	1,550,630	460	879,040
Warrant liability, less current portion		3,690,806	5,352,663
Recurring [Member] \| Quoted Prices in Active Markets for Identical Instruments (Level 1) [Member]
Assets
Short-term investments in mutual fund debt securities	5,015,171	5,001,494	5,004,315
Liabilities
Warrant liability, current portion
Warrant liability, less current portion
Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Assets
Short-term investments in mutual fund debt securities
Liabilities
Warrant liability, current portion	1,550,630	460	879,040
Warrant liability, less current portion		3,690,806	5,352,663
Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Assets
Short-term investments in mutual fund debt securities
Liabilities
Warrant liability, current portion
Warrant liability, less current portion

Investments (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Investments [Abstract]
Mutual fund debt securities	$ 5,015,171	$ 5,001,494	$ 5,004,315
Enhanced yield time deposits		448,632	458,098
Total short-term investments	$ 5,015,171	$ 5,450,126	$ 5,462,413

Inventory (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Inventory [Abstract]
Raw materials	$ 42,549	$ 10,480
Work in process	137,021	24,411
Finished goods	377,710
Inventory	$ 557,280	$ 34,891

Property, Plant and Equipment, net (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Property, Plant and Equipment, net [Abstract]
Depreciation expense	$ 12,529	$ 159,521	$ 132,122	$ 96,262

Property, Plant and Equipment, net (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 1,114,821	$ 906,603	$ 893,126
Less: accumulated depreciation	(643,492)	(518,263)	(505,734)
Depreciable assets, net	471,329	388,340	387,392
Construction in progress	32,079
Property, plant and equipment, net	503,408	388,340	387,392
Aquaculture system [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	124,529	58,923	58,923
Laboratory facilities [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	62,033	62,033	62,033
Computer and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	78,936	77,697	77,697
Tools and equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	714,764	635,766	622,289
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	10,997	10,997	10,997
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 123,562	$ 61,187	$ 61,187

Intangible Assets - Licensing Rights (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2011
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense			$ 26,191	$ 28,571
Impairment loss			90,476
General and Administrative Expense [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment loss			$ 90,476
Licensing Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Licence fee for the licensing rights					$ 200,000
Estimated useful life		7 years

Commitments (Narrative) (Details) - USD ($)	1 Months Ended		12 Months Ended
Commitments (Narrative) (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Operating Leased Assets [Line Items]
Rent expense on lease agreements		$ 15,000	$ 192,000	$ 181,000	$ 178,000
Three buildings and facilities used in its operations [Member]
Operating Leased Assets [Line Items]
Lease agreement, contract term			5 years
Lease agreement, renewal term			5 years
Lease contract/renewal start date			2015-10
Facilities used for executive offices and laboratories [Member]
Operating Leased Assets [Line Items]
Lease agreement, renewal term			2 years
Lease contract/renewal start date			2014-07
Undeveloped land in Baja, Mexico
Operating Leased Assets [Line Items]
Lease agreement, contract term			3 years
Lease agreement, renewal term			30 years
Lease contract/renewal start date			2015-06
Rent prepaid in June 2015	$ 74,606
Agreements with contract manufacturing organizations and consultants [Member]
Purchase Obligations [Line items]
Purchase obligations			$ 423,000
Agreements to pay time and materials to contractors [Member]
Purchase Obligations [Line items]
Purchase obligations			6,000
401(k) Retirement Savings Plan [Member]
Other Commitments [Line Items]
Employer contributions		5,000	$ 58,000	52,000	71,000
Employee vesting percentage			100.00%
Annual non-elective safe harbor employer contribution			3.00%
Licensing Agreements [Member]
Other Commitments [Line Items]
License costs		20,000	$ 20,000	200,000	25,000
Annual license fee			$ 20,000
Annual license fee, start date			2014-09
Patent cost reimbursement			$ 52,000	34,000	$ 51,000
Common shares issued upon execution of licence agreement					37,120
Common shares to be called by warrants					27,840
Aggregate milestone payments upon achievement of financing and development targets			6,020,000
Contingent milestone payments due upon achievement of sales target			$ 57,025,000
Milestone payment				100,000
Director and Officer [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Royalty percentage of gross receipts over base amount			5.00%
Gross receipt base amount for royalty calculation			$ 500,000
Royalty expense			$ 1,500
A Taiwan Biopharmaceuticals Manufacturer and a Beneficial Owner [Member] \| Collaborative Agreement [Member]
Related Party Transaction [Line Items]
Ownership percentage			5.00%

Commitments (Schedule of Future Minimum Lease Payments) (Details)	Sep. 30, 2015 USD ($)
For The Year Ending September 30,
2016	$ 157,000
2017	143,000
2018	106,000
2019	106,000
2020	106,000
Thereafter	6,000
Future minimum lease payments, total	$ 624,000

Share Capital (Schedule of Transactions In Share Capital) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Share Capital [Abstract]
Number of common shares issued	115,100	42,773	2,032,269	1,253,260
Proceeds from exercise of warrants and broker units	$ 727,804	$ 12,609	$ 3,764,460	$ 1,510,336
Transfer to common shares on exercise of warrants and broker units	890,214	10,000	6,591,546	2,139,409
Proceeds from exercise of options	11,488	94,168	544,418	72,403
Transfer to common stock on exercise of options	13,533	113,561	489,136	54,325
Share-based compensation	$ 36,509	$ 267,222	$ 956,634	$ 786,585

Share Capital (Schedule of Warrants Activity) (Details)	1 Months Ended	12 Months Ended
Share Capital (Schedule of Warrants Activity) (Details)	Sep. 30, 2014 $ / shares shares	Sep. 30, 2015 $ / shares shares	Aug. 31, 2014 $ / shares shares	Aug. 31, 2014 $ / shares shares
Share Capital [Abstract]
Number of Warrants, Beginning Balance \| shares	1,151,971	1,054,531	1,132,630	1,132,630
Number of Warrants, Granted \| shares	4,260		3,810	3,810
Number of Warrants, Granted \| shares			604,761	604,761
Number of Warrants, Exercised \| shares	(101,700)	(3,900)	(583,230)	(583,230)
Number of Warrants, Exercised \| shares			(6,000)	(6,000)
Number of Warrants, Expired \| shares		(27,870)
Number of Warrants, Ending Balance \| shares	1,054,531	1,022,761	1,151,971	1,151,971
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 9.70	$ 10.10		$ 5.70
Weighted Average Exercise Price, Granted \| $ / shares	7.50			4.60
Weighted Average Exercise Price, Granted \| $ / shares			$ 13.30
Weighted Average Exercise Price, Exercised \| $ / shares	7.50	4.05		6.80
Weighted Average Exercise Price, Exercised \| $ / shares			$ 13.50
Weighted Average Exercise Price, Expired \| $ / shares		12.50
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 10.10	$ 12.12		$ 9.70

Share Capital (Summary of Outstanding Warrants) (Details)

12 Months Ended

Sep. 30, 2015

$ / shares

Sep. 30, 2015

$ / shares

Sep. 30, 2014

$ / shares

Aug. 31, 2014

$ / shares

Aug. 31, 2013

$ / shares

Class of Warrant or Right [Line Items]

Exercise Price | $ / shares

$ 12.12

$ 10.10

$ 9.70

$ 5.70

Number of Warrants | shares

1,022,761

1,054,531

1,151,971

1,132,630

Warrant One [Member]

Class of Warrant or Right [Line Items]

Exercise Price | $ / shares

$ 4.00

Number of Warrants | shares

400,000

Expiry Date

^[1]

Oct. 25, 2015

Warrant Two [Member]

Class of Warrant or Right [Line Items]

Exercise Price | $ / shares

$ 4.00

Number of Warrants | shares

24,000

Expiry Date

Jan. 04, 2016

Warrant Three [Member]

Class of Warrant or Right [Line Items]

Exercise Price | $ / shares

$ 13.50

Number of Warrants | shares

470,190

Expiry Date

Sep. 09, 2016

Warrant Five [Member]

Class of Warrant or Right [Line Items]

Exercise Price | $ / shares

$ 13.50

Number of Warrants | shares

95,238

Expiry Date

Sep. 20, 2016

Broker warrants [Member] | Warrant Four [Member]

Class of Warrant or Right [Line Items]

Exercise Price | $ / shares

$ 10.50

Number of Warrants | shares

20,000

Expiry Date

Sep. 09, 2016

Broker warrants [Member] | Warrant Six [Member]

Class of Warrant or Right [Line Items]

Exercise Price | $ / shares

$ 10.50

Number of Warrants | shares

13,333

Expiry Date

Sep. 20, 2016

[1]	Subsequently exercised.

Share Capital (Schedule Of Warrants Exercised, Fair Value Assumptions) (Details) - Warrants Exercised [Member]	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Class of Warrant or Right [Line Items]
Risk free interest rate	1.12%	0.44%	1.07%	1.23%
Expected life (years)	11 days	4 months 24 days	3 months 7 days	1 year 2 months 1 day
Expected share price volitility	97.00%	92.00%	106.00%	111.00%

Share Capital (Schedule Of Warrants Granted, Fair Value Assumptions) (Details) - Warrants Granted [Member]	12 Months Ended
	Aug. 31, 2014	Aug. 31, 2013
Class of Warrant or Right [Line Items]
Risk free interest rate	1.48%	1.18%
Expected life (years)	3 years	2 years 9 months 4 days
Expected share price volitility	112.00%	123.00%
Expected dividend yield	0.00%	0.00%

Share Capital (Schedule of Broker Units Activity) (Details) - $ / shares	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014
Share Capital [Abstract]
Number of units, Beginning Balance	55,120	46,720	59,620
Number of units, Exercised	(8,400)	(120)	(4,500)
Number of units, Ending Balance	46,720	46,600	55,120
Weighted average exercise price, Beginning Balance	$ 2.90	$ 2.51	$ 2.90
Weighted average exercise price, Exercised	5.00	5.00	3.30
Weighted average exercise price, Ending Balance	$ 2.51	$ 2.50	$ 2.90

Share Capital (Summary of Outstanding Broker Units) (Details) - $ / shares

12 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Aug. 31, 2014

Aug. 31, 2013

Class of Warrant or Right [Line Items]

Number of Units

46,600

46,720

55,120

59,620

Broker Unit One [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 2.50

Number of Units

40,000

Expiry Date

^[1]

Oct. 25, 2015

Broker Unit Two [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 2.50

Number of Units

6,600

Expiry Date

Jan. 04, 2016

[1]	Subsequently exercised.

Share Capital (Schedule Of Broker Units Granted, Fair Value Assumptions) (Details) - Broker Units Granted [Member]	12 Months Ended
	Aug. 31, 2013
Class of Warrant or Right [Line Items]
Risk free interest rate	1.17%
Expected life (years)	2 years 9 months 29 days
Expected share price volitility	123.00%
Expected dividend yield	0.00%

Share Capital (Schedule of Share Option Activity) (Details)	1 Months Ended	12 Months Ended
	Sep. 30, 2014 $ / shares shares	Sep. 30, 2015 $ / shares shares	Aug. 31, 2014 $ / shares shares	Aug. 31, 2014 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance \| shares	593,553	588,553	658,887	658,887
Number of Options, Granted \| shares		16,500	19,500	19,500
Number of Options, Granted \| shares			59,500	59,500
Number of Options, Exercised \| shares	(5,000)	(38,750)	(144,167)	(144,167)
Number of Options, Expired \| shares		(8,665)	(167)	(167)
Number of Options, Ending Balance \| shares	588,553	557,638	593,553	593,553
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 6.10	$ 6.20		$ 4.20
Weighted Average Exercise Price, Granted \| $ / shares		13.30		14.20
Weighted Average Exercise Price, Granted \| $ / shares			$ 18.30
Weighted Average Exercise Price, Exercised \| $ / shares	2.50	3.06		4.10
Weighted Average Exercise Price, Expired \| $ / shares		14.21		4.20
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 6.20	$ 6.93		$ 6.10

Share Capital (Summary of Share Options Outstanding and Exercisable) (Details)	12 Months Ended
	Sep. 30, 2015 $ / shares shares	Sep. 30, 2015 $ / shares shares	Sep. 30, 2014 shares	Aug. 31, 2014 shares	Aug. 31, 2013 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	557,638	557,638	588,553	593,553	658,887
Exercisable at September 30, 2015	545,137	545,137
Stock Option Group One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	306,110	306,110
Exercisable at September 30, 2015	306,110	306,110
Exercise Price Range, Lower Range Limit \| $ / shares		$ 0.00
Exercise Price Range, Upper Range Limit \| $ / shares		$ 5.00
Expiry Date, Start	2017-04	2017-04
Expiry Date, End	2019-12	2019-12
Stock Option Group Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	173,861	173,861
Exercisable at September 30, 2015	169,027	169,027
Exercise Price Range, Lower Range Limit \| $ / shares		$ 5.01
Exercise Price Range, Upper Range Limit \| $ / shares		$ 10.00
Expiry Date, Start	2017-10	2017-10
Expiry Date, End	2022-06	2022-06
Stock Option Group Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	21,500	21,500
Exercisable at September 30, 2015	13,833	13,833
Exercise Price Range, Lower Range Limit \| $ / shares		$ 15.01
Exercise Price Range, Upper Range Limit \| $ / shares		$ 20.00
Expiry Date, Start	2018-11	2018-11
Expiry Date, End	2021-11	2021-11
Stock Option Group Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	56,167	56,167
Exercisable at September 30, 2015	56,167	56,167
Exercise Price Range, Lower Range Limit \| $ / shares	$ 15.01
Exercise Price Range, Upper Range Limit \| $ / shares	$ 20.00
Expiry Date, End	2020-11	2020-11

Share Capital (Schedule of Share Options Granted, Fair Value Assumptions) (Details) - Employee Stock Option [Member]	12 Months Ended
	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.65%	2.01%	1.55%
Expected life (years)	7 years	6 years 9 months	6 years 2 months 1 day
Expected share price volitility	115.00%	120.00%	123.00%
Expected dividend yield	0.00%	0.00%	0.00%

Share Capital (Narrative) (Details)	1 Months Ended	12 Months Ended
Share Capital (Narrative) (Details)	Sep. 30, 2014 CAD ($) $ / shares shares	Sep. 30, 2015 CAD ($) $ / shares	Aug. 31, 2014 CAD ($) $ / shares shares	Aug. 31, 2013 CAD ($) $ / shares shares	Sep. 30, 2015 USD ($) shares	Sep. 30, 2015 $ / shares	Sep. 01, 2015 shares	Aug. 31, 2012 shares
Share Capital [Line Items]
Common shares, shares outstanding	7,941,985		7,826,885		7,984,758
Stock split, description		<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">As a result of the reverse split, every ten shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share.</div>
Warrants, exercise price \| $ / shares	$ 10.10		$ 9.70	$ 5.70		$ 12.12
Weighted average contractual life remaining on the outstanding options		3 years 2 months 8 days
Weighted average fair value of share options awarded \| $ / shares		$ 11.72	$ 15.80	$ 3.80
Unrecognized share-based compensation expense \| $					$ 38,000
Unrecognized share-based compensation expense, recognition period		1 year 3 months
Intrinsic value of the options exercised \| $	$ 17.40	$ 10.14	$ 13.76	$ 6.67
Intrinsic value of the vested options \| $					$ 3.95
Warrant [Member]
Share Capital [Line Items]
Weighted average contractual life remaining on the outstanding warrants or broker units		7 months
Broker units [Member]
Share Capital [Line Items]
Weighted average contractual life remaining on the outstanding warrants or broker units		1 month
Weighted average fair value of warrants or broker units granted \| $ / shares				$ 2.50
Common Shares [Member]
Share Capital [Line Items]
Shares issued to acquire license (in shares)				37,120
Warrants, exercise price \| $ / shares				$ 12.50
Common shares to be called by warrants				27,840
Common shares to be called by each warrant				1
Performance Shares [Member]
Share Capital [Line Items]
Share based compensation, shares reserved for issuance								1,000,000
Share based compensation, shares outstanding					383,838
Employee Share Option [Member]
Share Capital [Line Items]
Share based compensation, shares reserved for issuance					1,000,000
Share based compensation, share option vesting schedule		Share options granted to directors, officers, employees and consultants are subject to the following vesting schedule: (a) One-third shall vest immediately; (b) One-third shall vest 12 months from the date of grant; and (c) One-third shall vest 18 months from the date of grant. Share options granted to investor relations consultants vest over a period of not less than 12 months as to 25% on the date that is three months from the date of grant, and a further 25% on each successive date that is three months from the date of the prior vesting.
Before Reverse Split Adjustment [Member]
Share Capital [Line Items]
Common shares, shares outstanding							79,847,550

Income Taxes (Schedule of Breakdown of Loss Before Income Tax by Jurisdiction) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Income Taxes [Abstract]
U.S.	$ (334,841)	$ (3,258,355)	$ (4,183,392)	$ (2,082,441)
Canadian	1,462,652	405,203	(4,096,931)	(12,412,538)
Other foreign	3,893	46,923	(132,000)
Total Loss Before Income Tax	$ 1,131,704	$ (2,806,229)	$ (8,412,323)	$ (14,494,979)

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014	Aug. 31, 2013
Deferred income tax assets:
Non-capital loss carry-forwards	$ 8,028,900	$ 6,561,000	$ 6,418,300	$ 4,426,800
Research and development tax credits	716,400	626,900	616,600	450,400
Deferred expenses	82,900	84,000	90,000	65,100
Property, plant and equipment	1,700
Share issuance costs	67,800	124,700	131,800	63,300
Deferred income tax liabilities:
US federal benefit net of state taxes	(628,800)	(517,100)	(509,000)	(350,600)
Property, plant and equipment		(13,600)	(14,500)	(33,400)
Valuation allowance	(8,268,900)	$ (6,865,900)	(6,733,200)	(4,621,600)
Net deferred income tax asset (liability)

Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Income Taxes [Abstract]
Combined Canadian federal and provincial tax rates	26.00%	26.00%	26.00%	25.00%
Expected income tax (recovery)/expense	$ 294,300	$ (729,600)	$ (2,187,200)	$ (3,623,700)
Nondeductible share-based payments	9,500	69,500	248,700	327,000
Nondeductible change in fair value of warrant liability	(436,800)	(554,100)	659,300	2,807,300
Effect of higher income tax rate in US	(46,000)	(445,800)	(602,100)	(308,400)
Foreign currency differences	25,400	169,900	(50,900)	(26,300)
Other	(3,800)	(43,300)	(219,800)	(322,500)
Change in valuation allowance on deferred tax assets	161,200	1,570,200	2,179,200	1,147,400
Income tax expense	$ 3,800	$ 36,800	$ 27,200	$ 800

Income Taxes (Schedule of Components of Income Tax Expense (Benefit)) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Current tax provision
U.S. federal
Canadian
Other foreign	3,000	36,000	26,400
State	800	800	800	800
Deferred tax provision
U.S. federal	(107,100)	(1,032,200)	(1,431,400)	(738,000)
Canadian	(21,600)	(209,300)	(289,800)	(157,500)
State	(32,500)	(328,700)	(458,000)	(251,900)
Change in valuation allowance on deferred tax assets	161,200	1,570,200	2,179,200	1,147,400
Total	$ 3,800	$ 36,800	$ 27,200	$ 800

Income Taxes (Narrative) (Details) - 12 months ended Sep. 30, 2015	USD ($)	CAD ($)
Federal [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 16,685,000
Federal [Member] \| Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2030
Federal [Member] \| Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035
Federal [Member] \| Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax Credit Carryforward, Amount	$ 339,000
Federal [Member] \| Research Tax Credit Carryforward [Member] \| Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2024
Federal [Member] \| Research Tax Credit Carryforward [Member] \| Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035
California [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 16,455,000
California [Member] \| Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2016
California [Member] \| Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035
California [Member] \| Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax Credit Carryforward, Amount	$ 377,000
Canadian [Member]
Income Tax [Line Items]
Operating Loss Carryforwards		$ 4,647,000
Canadian [Member] \| Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2028
Canadian [Member] \| Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Schedule of Supplemental Disclosure of Cash Flow Information) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Cash paid during the period for taxes	$ 800	$ 36,800	$ 30,200	$ 800

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Schedule of Supplemental Disclosure of Non-cash Financing and Investing Activities) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Share issuance costs - broker units and warrants			$ 386,898	$ 150,894
Transfer to common shares on exercise of warrants and broker units	890,214	10,000	6,591,546	2,139,409
Transfer to common shares on exercise of options	13,533	113,561	489,136	54,325
Transfer to common shares on issuance of performance shares			422,728
Shares subscribed transferred to common stock			5,155,674
Warrant valuations on private placements				1,749,004
Fair value of shares issued for acquisition of license				491,408
Warrant valuation on acquisition of license				$ 195,014

Concentrations of Credit Risk (Details)	1 Months Ended	12 Months Ended
Concentrations of Credit Risk (Details)	Sep. 30, 2014	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2013
Customer Concentration Risk [Member] \| Product sales and contract services revenue [Member] \| Five Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage		85.00%
Customer Concentration Risk [Member] \| Product sales and contract services revenue [Member] \| Three Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	86.00%
Customer Concentration Risk [Member] \| Product sales and contract services revenue [Member] \| Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage			73.00%	73.00%
Customer Concentration Risk [Member] \| Grant revenue [Member] \| One Grantor [Member]
Concentration Risk [Line Items]
Concentration risk percentage			100.00%	100.00%
Customer Concentration Risk [Member] \| Accounts receivable [Member] \| Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	81.00%	91.00%
Customer Concentration Risk [Member] \| Accounts receivable [Member] \| One Customer [Member]
Concentration Risk [Line Items]
Concentration risk percentage			76.00%
Customer Concentration Risk [Member] \| Accounts receivable [Member] \| One Grantor [Member]
Concentration Risk [Line Items]
Concentration risk percentage				88.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| Europe [Member]
Concentration Risk [Line Items]
Concentration risk percentage	9.00%	53.00%	41.00%	84.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| Asia [Member]
Concentration Risk [Line Items]
Concentration risk percentage	28.00%	38.00%	40.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| U.S. [Member]
Concentration Risk [Line Items]
Concentration risk percentage	62.00%	9.00%	14.00%	12.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| Other countries [Member]
Concentration Risk [Line Items]
Concentration risk percentage			6.00%	4.00%

Subsequent Events (Details)	1 Months Ended	2 Months Ended	12 Months Ended
Subsequent Events (Details)	Sep. 30, 2014 USD ($) shares	Dec. 01, 2015 CAD ($) shares	Sep. 30, 2015 USD ($) shares	Aug. 31, 2014 USD ($) shares	Aug. 31, 2013 USD ($)
Subsequent Event [Line Items]
Proceeds from exercise of warrants and broker units \| $	$ 727,804		$ 12,609	$ 3,764,460	$ 1,510,336
Number of warrants exercised	101,700		3,900	583,230
Number of broker units exercised	8,400		120	4,500
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from exercise of warrants and broker units \| $		$ 1,700,000
Common shares issued upon exercise of warrants and broker units		440,000
Number of warrants exercised		400,000
Number of broker units exercised		40,000